Penny stocks are a popular investment choice due to high inflation these days. What are we talking about with penny stocks here? Primarily, because they are easy to invest in and are able to make money quickly. Thanks to Robinhood, retail investors have access to the market. As penny stocks break out, you can see the real retail momentum. If you are interested in investing, you should check out Robinhood Penny Stock List.
Best Robinhood Penny Stocks To Buy:
Historically, Robinhood may not be the most famous platform for trading penny stocks. However, the broker has flourished owing to its easy-to-use interface, which attracts more investors and traders. In this discussion Stocks Telegraph will be discussing the Robinhood penny stock list for investors who trade through Robinhood for investing in it.
Cyclacel Pharmaceuticals Inc. (CYCC)
Cyclacel Pharmaceuticals Inc. (CYCC) stock closed last session at $1.37, increasing 8.73% or $0.11. Shares of the company fluctuated between $1.24 and $1.41 throughout the day. The number of shares exchanged was 0.11 million, less than the company’s 50-day daily volume of 0.93 million and lower than its Year-to-date volume of 0.49 million. In the past 12 months, the company’s stock has advanced -75.62%, and in the last one week, the stock has moved down -2.14%. For the last six months, the stock has lost a total of -57.59%, and over the last three months, the stock has decreased by -7.43%. The stock has returned -64.78% so far this year.
DELLORA INVESTMENTS LP bought a fresh place in Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC). The institutional investor bought 648.8 thousand shares of the stock in a transaction took place on 8/11/2022. In another most recent transaction, which held on 6/30/2022, MILLENNIUM MANAGEMENT LLC bought approximately 104.4 thousand shares of Cyclacel Pharmaceuticals Inc. In a separate transaction which took place on 6/30/2022, the institutional investor, ACADIAN ASSET MANAGEMENT LLC bought 66.1 thousand shares of the company’s stock. The total Institutional investors and hedge funds own 28.70% of the company’s stock.
About Cyclacel:
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis.
Corporate Governance:
Cyclacel Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A. Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Momentus Inc. (MNTS)
On Wednesday, shares in Momentus Inc. (MNTS) rise 7.14% to close the day at $1.50 which is a good figure for investors who want to invest in robinhood penny stocks. The volume of shares traded was 0.32 million, which is lower than the average volume over the last three months of 535.77K. During the trading session, the stock oscillated between $1.37 and $1.52. The company had an earnings per share ratio of -0.74. MNTS’s stock has lost -7.41% of its value in the previous five sessions and -18.03% over the past one month, but has lost -64.11% on year-to-date basis. The stock’s 50-day moving average of $1.8388 is above the 200-day moving average of $2.7668. Moreover, the stock is currently trading at RSI of 37.66.
Multiple groups of Wall Street analysts have recently been drawn to the MNTS stock, with those at Evercore ISI Initiated the stock to a “an Underperform”. The analysts released their assessment via a research note they published July 05, 2022. Analysts at Deutsche Bank maintained their earlier rating, although they did raise the stock’s price target to $10.
Momentus Inc., together with its subsidiaries, operates as a commercial space company. The company focuses on providing in-space infrastructure services, including in-space transportation, hosted payloads, and in-orbit services. Its principal and target customers include satellite operators. The company is headquartered in San Jose, California.
Iveda Solutions Inc. (IVDA)
Iveda Solutions Inc. (IVDA) stock gained 24.19% to close Wednesday’s session at $0.67 giving a good news to Robinhood penny stocks investors. The stock volume remained 45276.0 shares, which was lower than the average daily volume of 0.46 million shares within the past 50 days. IVDA shares have fallen by -89.66% over the last 12 months, and they have moved down by -6.94% in the past week. Over the past three months, the stock has lost -53.79%, while over the past six months, it has shed -91.45%. Further, the company has a current market of $8.82 million and its outstanding shares stood at 11.68 million.
Focusing on the company’s market volatility shows that it has a 1-Week Volatility index of 26.71%, and 14.96% for the month. This stock’s Average True Range (ATR) currently stands at 0.11, with the beta factor poised at -3.68. The indicator of Volatility helps exhibit the extent to which a stock is likely to plummet or climb when the rest of the market also dips or surges. If a stock has a beta score above 1, then its rate of volatility is high. Figures lower than 1, therefore, means that the stock’s volatility at that particular moment is low.
Iveda Solutions, Inc. provides artificial intelligence (AI) and digital transformation technologies in the United States and Taiwan. The company offers IvedaAI, a deep-learning video analytics software; IvedaPinpoint, a solution that manages Bluetooth trackers and sensors, and displays them on a map for exact location; Sentir Video, a video surveillance solution for various kinds of applications; Cerebro, a software technology platform that integrates a multitude of disparate systems for central access and management of applications, subsystems, and devices; and IvedaSPS, a smart power solution. In addition, it offers AI intelligent video search, smart utility, smart sensors, gateways, trackers, and IoT platforms. It serves airports, commercial buildings, government customers, data centers, shopping centers, hotels, banks, and safe city projects. The company was founded in 2003 and is based in Mesa, Arizona.
Phio (PHIO)
PHIO stock subtracted -2.05% to finish last trading session at $0.60. The stock recorded a trading volume of 12755.0 shares, which is below the average daily trading volume published for the last 50 days of 0.1 million shares. The shares of Phio have advanced -7.31% in the last five days; however, they have lost -14.61% over the last one month. The stock price has shed -16.93% over the last three months and has lost -70.89 percent so far this year.
Volatility is just a proportion of the anticipated day by day value extend—the range where an informal investor works. Greater instability implies more noteworthy benefit or misfortune. After an ongoing check, PHIO stock is found to be 5.69% volatile for the week, while 5.89% volatility is recorded for the month. The outstanding shares have been calculated 13.66M. Based on a recent bid, its distance from 20 days simple moving average is -11.56%, and its distance from 50 days simple moving average is -14.43% while it has a distance of -28.56% from the 200 days simple moving average.
Phio develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies.
Mullen Automotive Inc. (MULN)
The stock of Mullen Automotive Inc. (MULN) gained 7.10% to complete the last trading session at $0.36. The price range of the company’s shares was between $0.319 and $0.3739. It traded 72.56 million shares, which was below its daily average of 74.48 million shares over 100 days. MULN’s shares have dropped by -12.36% in the last five days, while they have subtracted -42.32% in the last month. Further, it is currently trading at a price to book ratio of 7.12.
According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market Index has added its position in Mullen Automotive Inc. (MULN) to 8,990,451 shares, mirroring a recent increase by 2.18%. Vanguard Total Stock Market Index added 0.19 million shares of Mullen Automotive Inc. common stock bringing its total worth to about $6.0 million at the end of recent close, SEC documents show. Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by Vanguard Extended Market Index Fu, which sold off 0.0 shares to end up with 3,305,925 shares worth $2.21 million. iShares Russell 2000 ETF raise their holdings by 0.54% in the company over the course of the most recent quarter. It now holds a 0.09% position in Mullen Automotive Inc. thanks to 0.44 million shares amounting to $0.3 million.
Mullen Automotive, Inc., an electric vehicle company, manufactures and distributes electric vehicles. It also operates CarHub, a digital platform that leverages AI to offer an interactive solution for buying, selling, and owning a car; and provides battery technology and emergency point-of-care solutions. The company was founded in 2014 and is based in Brea, California.
